Literature DB >> 33517156

Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study.

Misbah Baqir1, Amit Vasirreddy2, Ann N Vu3, Teng Moua3, Alanna M Chamberlain4, Ryan D Frank4, Jay H Ryu3.   

Abstract

BACKGROUND: It is unknown whether gastroesophageal reflux disease (GERD) is a risk factor or consequence of idiopathic pulmonary fibrosis (IPF). This study aimed to determine whether patients with IPF were more likely to have GERD compared with age- and sex-matched controls who either had 1) interstitial lung disease (ILD) other than IPF or 2) no diagnosed lung disease (population control).
METHODS: We used the medical records-linkage system of the Rochester Epidemiology Project (REP) to identify patients with IPF who resided in Olmsted County, Minnesota, from January 1, 1997, through June 30, 2017. IPF cases were each matched with patients from 2 control groups (non-IPF ILD controls and population controls). We used conditional logistic regression to model associations between GERD diagnosis and IPF case status. P values were adjusted for multiple comparisons by using the Bonferroni adjustment (P values < .025 were considered statistically significant).
RESULTS: One hundred thirteen IPF cases were identified and matched to 226 population controls and 226 controls with non-IPF ILD. After multivariable adjustment, the odds of having GERD were 1.78 times higher (95% CI, 1.09-2.91; P = .02) in IPF cases compared with population controls. After multivariable adjustment, the odds of having GERD were 0.46 times lower (95% CI, 0.23-0.94; P = .03) in IPF cases compared with non-IPF ILD controls.
CONCLUSION: GERD may be an important contributor to the development of lung fibrosis. Thus, it should be investigated and addressed adequately when detected in patients with IPF and patients with non-IPF ILD.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Gastroesophageal reflux; Idiopathic pulmonary fibrosis; Interstitial lung disease

Mesh:

Year:  2021        PMID: 33517156      PMCID: PMC7938662          DOI: 10.1016/j.rmed.2021.106309

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   4.582


  51 in total

1.  Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment.

Authors:  Marco E Allaix; Piero M Fisichella; Imre Noth; Fernando A Herbella; Bernardo Borraez Segura; Marco G Patti
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

Review 2.  Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.

Authors:  Ganesh Raghu; Valeria C Amatto; Jürgen Behr; Susanne Stowasser
Journal:  Eur Respir J       Date:  2015-10       Impact factor: 16.671

3.  Lung pH and pulmonary absorption of nonvolatile drugs in the rat.

Authors:  L S Schanker; M J Less
Journal:  Drug Metab Dispos       Date:  1977 Mar-Apr       Impact factor: 3.922

4.  Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation.

Authors:  Matthew P Sweet; Marco G Patti; Lorriana E Leard; Jeffrey A Golden; Steven R Hays; Charles Hoopes; Pierre R Theodore
Journal:  J Thorac Cardiovasc Surg       Date:  2007-02-22       Impact factor: 5.209

5.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

6.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.

Authors:  Willy Gomm; Klaus von Holt; Friederike Thomé; Karl Broich; Wolfgang Maier; Anne Fink; Gabriele Doblhammer; Britta Haenisch
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

Review 7.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.

Authors:  Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton
Journal:  Mayo Clin Proc       Date:  2012-11-28       Impact factor: 7.616

8.  Gastric juice from patients "on" acid suppressive therapy can still provoke a significant inflammatory reaction by human bronchial epithelial cells.

Authors:  Veerle Mertens; Kathleen Blondeau; Bart Vanaudenaerde; Robin Vos; Ricard Farre; Ans Pauwels; Geert Verleden; Dirk Van Raemdonck; Lieven Dupont; Daniel Sifrim
Journal:  J Clin Gastroenterol       Date:  2010 Nov-Dec       Impact factor: 3.062

Review 9.  Respiratory disease and the oesophagus: reflux, reflexes and microaspiration.

Authors:  Lesley A Houghton; Augustine S Lee; Huda Badri; Kenneth R DeVault; Jaclyn A Smith
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-06       Impact factor: 46.802

10.  Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry.

Authors:  Helen E Jo; Tamera J Corte; Ian Glaspole; Christopher Grainge; Peter M A Hopkins; Yuben Moodley; Paul N Reynolds; Sally Chapman; E Haydn Walters; Christopher Zappala; Heather Allan; Gregory J Keir; Wendy A Cooper; Annabelle M Mahar; Samantha Ellis; Sacha Macansh; Nicole S Goh
Journal:  BMC Pulm Med       Date:  2019-05-03       Impact factor: 3.317

View more
  3 in total

Review 1.  Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know.

Authors:  Elena K Joerns; Traci N Adams; Jeffrey A Sparks; Chad A Newton; Bonnie Bermas; David Karp; Una E Makris
Journal:  Curr Rheumatol Rep       Date:  2022-06-01       Impact factor: 4.686

2.  Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies.

Authors:  Yongpeng Ge; Hanbo Yang; Xinyue Xiao; Lin Liang; Xin Lu; Guochun Wang
Journal:  BMC Pulm Med       Date:  2022-01-10       Impact factor: 3.317

Review 3.  Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?

Authors:  Barbara Ruaro; Riccardo Pozzan; Paola Confalonieri; Stefano Tavano; Michael Hughes; Marco Matucci Cerinic; Elisa Baratella; Elisabetta Zanatta; Selene Lerda; Pietro Geri; Marco Confalonieri; Francesco Salton
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.